Europe fares badly when it comes to translating biomedical research into health innovation. The upcoming Innovative Health Initiative aims to improve things, pumping €2.2B into cross-sector projects
The Innovative Medicines Initiative project ZAPI has put in place a new pan-virus methodology for ramping up the production of new vaccines in the next crisis
As COVID-19 shows, older people are particularly vulnerable to infectious diseases. IMI’s VITAL project is studying vaccines and immunity in older adults, to figure out the best strategies to keep people healthier for longer.
From setting standards for genetic newborn screening to helping pharma create a shared platform to treat thousands of rare diseases, IMI is ready to help drive the science forward.
Head of Innovative Medicines Initiatives argues that the project’s technologies, knowledge and networks came together in the crisis. The successor programme must sustain these achievements and build on them
Pierre Meulien, director of the Innovative Medicines Initiative wants to see pooling of international research efforts to help curb the spread of COVID-19 and develop treatments for the respiratory infection it causes
Vaccines could offer hope - but who to vaccinate, and against what, has no clear answer yet. Read IMI Executive Director Dr Pierre Meulien’s perspective on what is needed to tackle antimicrobial resistance.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.